{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-046096","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.652696+00:00","generated_at":"2026-06-04T00:05:30.684507+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Black Diamond Therapeutics appoints Shannon Campbell and Prakash Raman to board; Dixon and Mayweg resign","bullets":["Wendy Dixon and Alex Mayweg resigned from board effective April 10, 2024; no disagreement cited.","Shannon Campbell (EVP/Chief Commercial Officer at Merus) appointed Class III director, will serve on Compensation Committee.","Prakash Raman (CEO of stealth biopharma) appointed Class I director, will serve on Audit and Nominating/Governance Committees.","New directors are independent under Nasdaq standards and will receive standard non-employee director compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-046096","json":"https://secwatch.observer/filing/0001104659-24-046096.json","markdown":"https://secwatch.observer/filing/0001104659-24-046096.md","text":"https://secwatch.observer/filing/0001104659-24-046096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/tm2411574d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:05:30.684507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73bdf27e38","claim":"Wendy L. Dixon resigned as Director at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c9f266ce2c","claim":"Prakash Raman was appointed as Director at Black Diamond Therapeutics, Inc..","evidence_excerpt":"the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f14ef7a6c3","claim":"Alexander Mayweg resigned as Director at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}